Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has a beta value of 0.86 and has seen 1,213,441 shares traded in the last trading session. The company, currently valued at $537.24 Million, closed the last trade at $11.55 per share which meant it gained $0.43 on the day or 3.87% during that session. The AERI stock price is -127.36% off its 52-week high price of $26.26 and 11.52% above the 52-week low of $10.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 770.46 Million shares traded. The 3-month trading volume is 721.76 Million shares.

The consensus among analysts is that Aerie Pharmaceuticals, Inc. (AERI) is a Buy stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 13 have rated it as a Hold, with 11 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.8.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) trade information

Sporting 3.87% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Sep 09 when the AERI stock price touched $12.33- or saw a rise of 6.33%. Year-to-date, Aerie Pharmaceuticals, Inc. shares have moved -52.21%, while the 5-day performance has seen it change -3.35%. Over the past 30 days, the shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) have changed -9.13%. Short interest in the company has seen 8.36 Million shares shorted with days to cover at 0.01.

Wall Street analysts have a consensus price target for the stock at $28, which means that the shares’ value could jump 142.42% from current levels. The projected low price target is $14 while the price target rests at a high of $50. In that case, then, we find that the current price level is +332.9% off the targeted high while a plunge would see the stock lose 21.21% from current levels.

Aerie Pharmaceuticals, Inc. (AERI) estimates and forecasts

Figures show that Aerie Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -17.56% over the past 6 months, with this year growth rate of -5%, compared to 16.1% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 7% and 19.8% for the next quarter. Revenue growth from the last financial year stood is estimated to be +15.6%.

12 analysts offering their estimates for the company have set an average revenue estimate of $19.77 Million for the current quarter. 12 have an estimated revenue figure of $22.68 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $18.54 Million and $24.66 Million respectively for this quarter and the next, and analysts expect sales will grow by 6.6% for the current quarter and -8% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -17.1% over the past 5 years. Earnings growth for 2020 is a modest +21.3%.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)’s Major holders

Insiders own 2.08% of the company shares, while shares held by institutions stand at 131.45% with a share float percentage of 134.25%. Investors are also buoyed by the number of investors in a company, with Aerie Pharmaceuticals, Inc. having a total of 240 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 4.26 Million shares worth more than $62.87 Million. As of June 29, 2020, Vanguard Group, Inc. (The) held 9.16% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 3.84 Million shares as of June 29, 2020. The firm’s total holdings are worth over $56.63 Million and represent 8.25% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Hartford Mid Cap Fund and Vanguard Total Stock Market Index Fund. As of April 29, 2020, the former fund manager holds about 6.96% shares in the company for having 3235378 shares of worth $49.31 Million while later fund manager owns 1.34 Million shares of worth $19.73 Million as of June 29, 2020, which makes it owner of about 2.87% of company’s outstanding stock.